

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAMXG1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	27	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	28	AUG 11	STN AnaVist workshops to be held in North America
NEWS EXPRESS.			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:33:03 ON 11 AUG 2005

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 16:33:27 ON 11 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Aug 2005 VOL 143 ISS 7

FILE LAST UPDATED: 10 Aug 2005 (20050810/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s mizoribine

L1 322 MIZORIBINE

=> s l1 and immuno

14629 IMMUNO

L2 1 L1 AND IMMUNO

=> d l2 bib abs

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:88327 CAPLUS

DN 128:200735

TI The synergistic effect of bactobolamine and tacrolimus in in vitro and in vivo experiments

AU Watanabe, Kenshi; Kikuchi, Kenji; Ichikawa, Naoya; Ando, Yuichi; Meigata, Kazuhiko; Nishimura, Yoji; Nomura, Yuji; Degawa, Toshikazu; Beck, Yoshifumi; Tomikawa, Shinji; Nagao, Takeshi; Uchida, Hisanori

CS Department of Organ Transplantation and Surgery, Institute of Medical Science, University of Tokyo, Tokyo, 108, Japan

SO Surgery Today (1997), 27(12), 1160-1166

CODEN: SUTOE5; ISSN: 0941-1291

PB Springer-Verlag Tokyo

DT Journal  
 LA English  
 AB The aim of this study was to examine the **immuno**-suppressive effect of bactobolamine (BBL) alone and in combination with tacrolimus (FK) using in vitro proliferation assays on human peripheral blood lymphocytes (PBLs) and in vivo liver allografts in rats. In the latter setting, the **immuno**-suppressive activity of BBL alone and in combination with FK was compared to that of **mizoribine** (MIZ). The interactions between BBL and FK and between MIZ and FK were assessed by the combination index (CI) proposed by Chou and Kahan. In the in vitro study, the combination of BBL and FK displayed stronger inhibitory effects on T-cell proliferation than when each drug was applied alone. The mean CI values for the BBL/FK combination were below 1.0, ranging from 0.19 to 0.86, indicating synergism between BBL and FK. In the in vivo study, 50-200 mg/kg/day BBL monotherapy significantly prolonged survival compared with a control group, and the effect was dose-dependent. Conversely, the efficacy of MIZ monotherapy at 2.5-10 mg/kg/day did not increase dose-dependently. The CIs for MIZ at doses of 2.5 and 5.0 mg/kg/day with FK 0.08 mg/kg/day were 0.48 and 0.42, resp., indicating therapeutic synergism between MIZ and FK. The CI for BBL 100 mg/kg/day with FK was 0.26, which indicated further synergism between BBL and FK.

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file medline		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.13	9.34
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'MEDLINE' ENTERED AT 16:36:57 ON 11 AUG 2005

FILE LAST UPDATED: 9 AUG 2005 (20050809/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s "inosine monophosphate dehydrogenase" or "impdh"
      7069 "INOSINE"
      37455 "MONOPHOSPHATE"
      128465 "DEHYDROGENASE"
      249 "INOSINE MONOPHOSPHATE DEHYDROGENASE"
          ("INOSINE" (W) "MONOPHOSPHATE" (W) "DEHYDROGENASE")
      263 "IMPDH"
L3      407 "INOSINE MONOPHOSPHATE DEHYDROGENASE" OR "IMPDH"

=> s 13 and immuno
      14400 IMMUNO
```

L4 1 L3 AND IMMUNO

=> d bib abs

L4 ANSWER 1 OF 1 MEDLINE on STN  
AN 97431100 MEDLINE  
DN PubMed ID: 9285199  
TI Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.  
AU Simmons W D; Rayhill S C; Sollinger H W  
CS Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, USA.. WD.SIMMONS@HOSP.WISC.EDU  
SO Drug safety : an international journal of medical toxicology and drug experience, (1997 Aug) 17 (2) 75-92. Ref: 68  
Journal code: 9002928. ISSN: 0114-5916.  
CY New Zealand  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199710  
ED Entered STN: 19971105  
Last Updated on STN: 19971105  
Entered Medline: 19971022  
AB Mycophenolate mofetil (the morpholinoethyl ester of mycophenolic acid) inhibits de novo purine synthesis via the inhibition of **inosine monophosphate dehydrogenase**. Its selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation. Mycophenolate mofetil has **immuno**-suppressive effects alone, but is used most commonly in combination with other immunosuppressants. Mycophenolate mofetil, in combination with cyclosporin and corticosteroids, has been studied in large, randomised clinical trials involving nearly 1500 renal allograft transplant recipients. These trials demonstrated that mycophenolate mofetil is significantly more effective in reducing treatment failure and acute rejection episodes than placebo or azathioprine. Additionally, mycophenolate mofetil may be able to reduce the occurrence of chronic rejection. Mycophenolate mofetil is relatively well tolerated. The most common adverse effect reported is gastrointestinal intolerance; haematological aberrations have also been noted. The reversible cytostatic action of mycophenolate mofetil allows for dose adjustment or discontinuation, preventing serious toxicity or an overly suppressed immune system. Cytomegalovirus tissue invasive disease and the development of malignancies are concerns that merit evaluation in long term follow-up studies. Mycophenolate mofetil does not cause the adverse effects typically associated with other commercially available immunosuppressant medications such as nephrotoxicity, hepatotoxicity, hypertension, nervous system disturbances, electrolyte abnormalities, skin disorders, hyperglycaemia, hyperuricaemia, hypercholesterolaemia, lipid disorders and structural bone loss. Based on preliminary information, a positive benefit-risk ratio has been demonstrated with the use of mycophenolate mofetil in the prophylaxis of rejection in cadaveric renal allograft transplantation. Data from studies in other types of organ transplants are promising, but are too limited to draw clear conclusions. Long term follow-up studies are required to confirm these observations. Although mycophenolate mofetil is expensive, the beneficial effects on the reduction of rejection, treatment failure and related expenses suggest that it is most likely to be cost effective.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	1.36	10.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-0.73

STN INTERNATIONAL LOGOFF AT 16:38:45 ON 11 AUG 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamxgl614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4	AUG 11	STN AnaVist workshops to be held in North America
NEWS 5	AUG 30	CA/CAPLUS - Increased access to 19th century research documents
NEWS 6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8	OCT 03	MATHDI removed from STN
NEWS 9	OCT 04	CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10	OCT 06	STN AnaVist workshops to be held in North America
NEWS 11	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPLUS documents for use in third-party analysis and visualization tools

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.